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Special Section: Bioethics and Health Disparities
Debating the Cause of Health Disparities
Implications for Bioethics and Racial Equality
DOROTHY ROBERTS
In 2002, the health arm of the National Academy of Sciences, the Institute of
Medicine (IOM), scientifically documented widespread racial disparities in health-
care and suggested that they stemmed, at least in part, from physician bias. Its
562-page report, Unequal Treatment: Confronting Racial and Ethnic Disparities in Health-
care, noted that, although these disparities are associated with socioeconomic status,
the majority of studies it surveyed ‘‘find that racial and ethnic disparities remain even
after adjustment for socioeconomic differences and other healthcare access-related
factors.’’1 As directed by Congress, the IOM committee defined ‘‘disparities’’ in
healthcare as ‘‘racial or ethnic differences in the quality of health care that are not
due to access-related factors or clinical needs, preferences, and appropriateness of
intervention’’ (pp. 3–4). Unequal Treatment concludes that, after factoring out these
access-related differences, remaining disparities can be attributed in part to dis-
crimination by the medical profession—physician prejudices, biases, or stereo-
typing of their minority patients.
Some commentators took offense at the report’s charge of racial bias. It was
unfair, they argued, to suggest that blatant racial prejudice, as was demonstrated
in the Tuskegee syphilis experiment, for example, still lingered in contemporary
medical care. ‘‘I would stress that the attitudes of physicians today have shown
a true revolution from those that permeated the generation or two ago,’’ wrote
University of Chicago law and economics professor Richard Epstein. ‘‘It is
a shame to attack so many people of good will on evidence that admits a much
more benign interpretation.’’2 The ‘‘benign’’ interpretations offered by critics
were that racial disparities stem from patient behavior, cultural difference,
biological difference, and economic inequality. Each of these explanations sounds
familiar to historians of race and health in America.
Although racial disparities in health are firmly established, pinpointing their
cause has been controversial. In this article, I challenge recent claims that racial
health disparities are caused by race-based genetic difference or race-neutral
economic difference on grounds that both explanations ignore the roots of health
disparities in social inequality. I develop my argument by examining the con-
troversy surrounding the Institute of Medicine report on racial bias in healthcare,
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biomedical research on race-based genetic difference, and advocacy for BiDil, the
first race-specific drug approved by the Food and Drug Administration, which
asserted that the therapy addressed racial disparities in heart failure. I argue that
focusing on race-neutral economic difference or race-based genetic difference
obscures the social inequalities that lead to poorer health among people of color,
as well as the need for social change.
Race-Neutral Economic Difference
In The Health Disparities Myth: Diagnosing the Treatment Gap, published by the
American Enterprise Institute in response to the IOM report, Sally Satel and
Jonathan Klick argue that variations in insurance coverage, medical practices,
and quality of physicians that are ‘‘correlated’’ with race are not evidence of
racial bias or injustice.3 Instead, they state that these are race-neutral factors that
result in inferior care that happens more often to people who are black. They
note, for example, that ‘‘as a rule, the quality of care received by blacks is inversely
related to the concentration of black residents in the local population’’ but caution
that ‘‘by focusing on race we miss a very important cause of health-care difference:
geography.’’4 In their view, geography independent of racism determines the
quality of healthcare, and black people happen to live in locations where health-
care is the worst.
In my view, it makes more sense to interpret the geography of healthcare as
evidence of racism: government and private business have developed inadequate
and inferior healthcare resources where black people are concentrated.5 Yet pro-
viding equal access to healthcare would not be enough to close the racial divide.
Racial inequality causes health disparities apart from blocking access to high-quality
care. It makes people of color sicker in the first place—before they get to a doctor’s
office or a hospital emergency room. Access to healthcare alone does not determine
an individual’s health, because health is affected primarily by the social environ-
ment. The way society is organized drives group disparities in health. Because they
reflect social inequality, a more accurate word for the racial gaps is health inequities.
As British public health champion Margaret Whitehead defines them, health
inequities are ‘‘systematic, socially produced (and therefore modifiable) and unfair,’’
and result from the unjust distribution of social, economic, political, and environ-
mental conditions that determine health.6
It has been firmly established that the best predictor of health is an individual’s
position in the social hierarchy. Hundreds of studies tracking the health of people
along the social ladder show that health gradually worsens as status declines.7
In any society, people with low socioeconomic status have poorer health than
people with higher socioeconomic status. The classic Whitehall Study of British
Civil Servants, lasting for more than two decades, published in 1978, compared
heart disease and mortality in employees at four civil service levels: administrators,
professional and executive employees, clerical staff, and menial workers. The
study found not only that the administrators at the top had far better health than
the janitors at the bottom, but also that health got worse and mortality increased
with each step down the occupational ladder.8 These social gradients in disease
occurred despite everyone’s access to the British universal healthcare system.
The question, then, becomes whether this relationship between economic
inequality and health applies equally to America’s glaring racial disparities.
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Racial inequality also produces huge gaps in advantage and disadvantage that
parallel the relative health of people in different racial groups. A growing
number of scientists from a variety of disciplines, including medicine, biology,
psychology, anthropology, and epidemiology, are investigating how racial inequi-
ties in income, housing, and education, along with experiences of stigma and
discrimination, translate into bad health. More than one hundred studies now
document the adverse effects of racial discrimination on health.9 Three of the main
biology-related pathways these researchers have identified are chronic exposure to
stress, segregation in unhealthy neighborhoods, and transmission of harms from
one generation to the next through the fetal environment.10 Their effects on health
stem specifically from racism that is separate from, and added to, the harmful
consequences of lower socioeconomic status.
A recent study of health in a racially integrated, low-income neighborhood of
southwest Baltimore, Maryland, highlighted the causal link between health
disparities and residential segregation, which leaves racial groups ‘‘exposed to
different health risks and with variable access to health services based on where
they live.’’11 The researchers found that when black and white Americans lived in
an integrated setting, the nationally reported gaps in hypertension, diabetes,
obesity among women, and use of health services either vanished or substantially
narrowed. The researchers did not interpret the study as showing that racial
inequality does not matter to health disparities; rather, they concluded that racial
differences in social environments explain a significant portion of the health
disparities revealed in national statistics.
The economic approach ignores the role of residential segregation in main-
taining inequitable treatment for blacks and fails to question why whites have the
privilege of living where there is better access to high-quality care. Instead of
explaining away race by adjusting for the myriad of factors that add up to
inferior healthcare, researchers should be asking why it is that being a person of
color in America is linked to all these negative factors. It is not bad luck: as the
studies mentioned previously show, blacks and other minorities are systemati-
cally denied access to equal treatment and exposed to conditions that are harm-
ful to their health. A proposed market solution will only reproduce—if not
worsen—disparities based on race, because it avoids the need to eliminate indi-
vidual and institutional bias.
Race-Based Genetic Difference
Whereas the economic explanation for health disparities ignores the impact of
race, another explanation focuses on race as a biological category. Countless
research projects at universities and biotech firms around the country search for
the genetic cause of health disparities in the United States. They are supplement-
ing a large body of published studies that claim to show that racial gaps in
disease prevalence or mortality are caused by genetic differences. Disparities in
asthma, infant mortality, diabetes, cancer, and hypertension have all been
attributed in the scientific literature to genetic vulnerability that varies according
to race. Most of these studies never even examined the genotypes of research
subjects; they inferred a genetic source of racial differences when they failed to find
another explanation.12
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Consider an effort to explain the enduring black–white gap in premature births
and low birth weight. A team of obstetric researchers examined all births in
Missouri between 1989 and 1997 to test the hypothesis that ‘‘black race independent
of other factors increases the risk of extreme preterm birth and its frequency of
recurrence.’’ The researchers used statistical methods to calculate the independent
influence of race, socioeconomic status (whether the mother was a recipient of
Medicaid, food stamps, or the WIC program), and maternal medical risk factors
such as lack of prenatal care and cigarette smoking. An article published in 2007 in
the American Journal of Obstetrics and Gynecology reported that black women were
more likely not only to deliver preterm babies but also to have preterm births in
subsequent pregnancies. Because this overrepresentation occurred even when they
controlled for medical and socioeconomic factors, the researchers concluded that
their findings ‘‘suggest a probable genetic component that may underlie the public
health problem presented by the racial disparity in preterm birth.’’ Although
conceding that they may have overlooked ‘‘hidden variables’’ that also contribute,
they nevertheless speculated about an unproven genetic mechanism operating in
‘‘the black race’’:
We postulate that although preterm birth is a detrimental outcome in
pregnancy, it may be a result of a selective advantage, conferring in-
flammatory protection against other disease processes. This selective
advantage phenomenon has been well described for diseases afflicting
the black race, particularly sickle cell disease, glucose-6-phosphate de-
hydrogenase deficiency, and nitrous oxide synthase polymorphisms and
their effects on the incidence of malaria.
The article ended by downplaying ‘‘disparate access to medical care or other
environmental factors,’’ arguing that ‘‘our data suggest that the proposed genetic
component to preterm birth may be a greater etiological contributor than
previously recognized’’—despite presenting no genetic data whatsoever.13
Despite its weaknesses, the Missouri birth study was dignified with a pub-
lished round table discussion in which commentators granted that ‘‘the genetic
link is very strong’’ and that the disparity ‘‘may best be explained by a genetic
etiology.’’14 The research also led to the headline ‘‘Study Points to Genetics in
Disparities in Preterm Births’’ in the New York Times, which repeated the totally
unsubstantiated conjecture that premature births may provide some evolutionary
advantage to black women. Neil Risch, a molecular biologist at the University of
California–San Francisco, criticized the study’s inference of a genetic cause
without ever examining genes. ‘‘They’re inferring something is genetic by
elimination of other factors,’’ he told the New York Times. ‘‘But geneticists believe
that to implicate something as genetic requires direct evidence, as opposed to
evidence of absence.’’15
Until recently, virtually every study of black hypertension accepted the premise
that blacks have higher rates of the disease than whites because of inherited
susceptibility.16 In volumes 27 through 30 of the scientific journal Hypertension,
published in 1996 and 1997, thirty articles hypothesized the existence of innate
physiological differences between racial groups.17 Since then, theories about the
precise genetic mechanism behind the hypertension gap are legion. Authors of
one study published in the Journal of Hypertension in 2000, for example, ‘‘postulate
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that the genetic factor increasing the propensity of black people of sub-Saharan
African descent to develop high blood pressure is the relatively high activity of
creatine kinase, predominantly in vascular and cardiac muscle tissue.’’18
A landmark study led by Richard Cooper contested the conventional wisdom
that blacks have an inherent predisposition to hypertension.19 Comparing
hypertension rates around the world, Cooper analyzed three surveys of blacks
from Africa, the Caribbean, and the United States and eight surveys of whites
from the United States, Canada, and Europe. Collectively, the studies enrolled
85,000 participants. If African Americans’ higher hypertension risk were genetic,
we would expect that people of African descent are more likely to have high
blood pressure than people of European descent. Instead, after pooling the global
data, Cooper found just the opposite. White populations on average have
a substantially higher burden of hypertension. Germans have the highest.
Nigerians have the lowest. U.S. whites come close to black Nigerians and
Jamaicans, whereas U.S. blacks come close to whites from England and Spain.
The whole body of genetic explanations for health disparities, both those that
infer a genetic cause and those that identify specific genes, is questionable. First,
most of these studies suffer from serious methodological flaws. They group
research subjects into conventional racial categories, fail to explain the relation-
ship between these social categories and genetic traits, and then reach con-
clusions about genetic difference among the subjects. A survey published in the
Journal of Medical Ethics in 2006 examined 268 published reports of genetic
research that used race as an independent variable.20 The research team found
that 72 percent of the studies failed to explain their methods for assigning race to
research subjects. Despite this glaring flaw, 67 percent of the same studies drew
conclusions associating genetics, health outcomes, and race.
Second, genetic explanations for health disparities are basically implausible.
Remember, the issue is not whether genes affect health—of course they do—but
whether genetic difference explains racial disparities in health. We would expect
social groups that have been systematically deprived for centuries to have worse
health than social groups that have been systematically privileged. The logical
cause is the social distance between them and all the ways societal advantage and
disadvantage affect people’s experiences, environments, and access to resources,
including healthcare. Likewise, it is implausible for a large group of people as
genetically diverse as African Americans to have such a concentrated genetic
susceptibility to so many common complex diseases. A more plausible hypoth-
esis given the persistence of unequal health outcomes along the social matrix of
race is that they are caused by social factors.
Studies that infer a genetic cause for health disparities typically control for the
socioeconomic status (SES) of the research subjects in an attempt to compare
subjects of different races who have the same SES. If there remains a difference in
the prevalence or outcome of a disease, the researchers attribute the unexplained
variation to genetic distinctions between racial groups. But this conclusion suffers
from a basic methodological error. The researchers failed to account for many
other unmeasured factors, such as the experience of racial discrimination or
differences in wealth, not just income, that are related to health outcomes and
differ by race. Any one of these unmeasured factors—and not genes—might
explain why the health outcomes vary by race. Statisticians call this the problem
of ‘‘residual confounding’’: falsely concluding that there is a causal relationship
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between two variables (here, genetics and disparate health outcomes) because
other variables are not measured.21
The hypothesis that health disparities are caused by genetic difference is
founded on a misunderstanding of race as a naturally created biological division
instead of a politically invented social division. Understanding race as a political
category that affects health requires changing the way we think about the
relationship between race and biology. Thomas LaViest, a leading public health
expert at Johns Hopkins, surveyed the use of race in epidemiological studies in
the 1990s. He found that most of the articles on U.S.-based populations did use
race, but the most common use was as a control variable—to filter out the impact
of race. So while geneticists were homing in on the biological impact of race,
epidemiologists were ignoring it. ‘‘What is needed is not simply more research on
race,’’ LaViest concluded, ‘‘but better research on race.’’22
Thinking on this issue tends to fall into two camps: either race is a social
category that has nothing to do with the biological causes of disease or race is
a biological category that causes differences in disease. Both approaches fail to
grasp the way in which race as a social grouping can affect health—because of
different life experiences based on race, not because of race-based genetic
difference.23 According to sociologist Troy Duster, ‘‘the task is to determine
how the social meaning of race can affect biological outcomes.’’24 Understanding
race as a political category does not erase its impact on biology; instead, it
redirects attention from genetic explanations to social ones.
Race-Specific Medicine as a Cure for Health Disparities
In June 2005, the Food and Drug Administration (FDA) announced a historic
decision: it approved the first pharmaceutical indicated for a specific race.25
BiDil, a combination drug that relaxes the blood vessels, was authorized to treat
heart failure in self-identified black patients. BiDil had been tested in the African-
American Heart Failure Trial, or A-HeFT, launched in 2001.26 A-HeFT enrolled
1,050 subjects suffering from advanced heart failure, all self-identified African
Americans. A-HeFT showed that BiDil worked; in fact, it worked so spectacularly
that the trial was stopped ahead of schedule. BiDil increased survival by an
astonishing 43 percent.27 Hospitalizations were reduced by 39 percent.28 Given
evidence of BiDil’s efficacy but little evidence that race mattered to its efficacy, the
FDA should have made one of two decisions: either reject the request for race-
specific approval or approve BiDil for all heart failure patients, regardless of race.
Instead, the FDA put race at the center of its decision, sparking controversy and
paving the way for a new generation of racial medicines.
The FDA explained its decision to approve BiDil specifically for black patients
by suggesting that race serves as a proxy for some underlying physiological
difference that might be genetic. In a January 2007 article in Annals of Internal
Medicine, two FDA scientists wrote, ‘‘We hope that further research elucidates the
genetic or other factors that predict the usefulness of hydralazine hydrochloride-
isosorbide dinitrate [the ingredients in BiDil]. Until then, we are pleased that one
defined group has access to a dramatically life-prolonging therapy.’’29 In other
words, a racially defined group could serve as a temporary substitute for the yet-
undiscovered genetic or other biological factor that identifies who will benefit
from BiDil.30
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Supporters of BiDil countered criticism of its racial label by arguing that race-
specific medicine is critical to advancing health by addressing health disparities
based on race.31 They claim that the health benefits outweigh the label’s power to
reinforce race as a biological category. Prominent African American scientists,
doctors, and advocates endorsed BiDil to redress past discrimination against
African Americans in medical treatment and access to healthcare. Ever since their
enslavement in the United States, African Americans have been victims of both
medical abuse, such as the infamous syphilis study in Tuskegee, Alabama, and
medical neglect.32 BiDil supporters argued that a race-specific drug fulfilled
a long-standing demand that science attend to the particular needs of African
Americans, who historically had been excluded from good medical care and
clinical trials while suffering disproportionately from heart disease. Representa-
tive Donna Christensen implored the FDA to approve BiDil as a remedy for medi-
cal wrongs against African Americans ‘‘for whom treatment has been denied and
deferred for 400 years.’’33
Many used the health disparities as a reason to ignore the scientific flaws in
race-based medicine. Gary Puckrein, executive director of the National Minority
Health Month Foundation, has championed BiDil as an important response to
high rates of heart disease among African Americans. Although he acknowl-
edged ‘‘concern about the medical and scientific validity of the concept of race,’’
he dismissed such concern as ‘‘under present circumstances, impractical.’’34
Similarly, Keith Ferdinand, chief science officer of the Association of Black
Cardiologists, wrote that ‘‘race lacks any true biologic definition,’’35 but BiDil is
a ‘‘life-saving drug’’36 that addresses ‘‘evidence of racial and ethnic differences in
cardiac care in the United States which may significantly affect health out-
comes.’’37 In other words, these BiDil advocates argue that the urgency of
addressing the African American health crisis with race-specific drugs overrides
objections that race is a social and not a genetic grouping.
Portraying BiDil as a solution to a racial gap in mortality implies the gap stems
from racial differences in disease and drug response. Adding a physiological
explanation for this difference attributes health disparities to flaws inside black
people’s bodies rather than to flaws in the society in which they live. It supports
the increasingly popular but misguided view that the tiny percentage of genetic
difference among human beings is distributed by race and that this difference
creates inequities in health.
Global Implications
The debate over the cause of health disparities has global implications.
Attributing gaps in health both within countries and among them to economic
or genetic differences can obscure the social and political inequalities that lead to
poorer health among the world’s most disadvantaged people. Perhaps the most
powerful evidence of the importance of social determinants is the relationship
between an entire nation’s health and its level of inequality. Numerous studies
tracking the health of people along the social ladder show that health gradually
worsens as socioeconomic status, including race, declines.38 In their recent book,
The Spirit Level, Richard Wilkinson and Kate Pinkett present remarkably consistent
evidence of ‘‘a very strong tendency for ill-health and social problems [including
reduced life expectancy and infant mortality] to occur less frequently in the more
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equal countries.’’39 Or to put it another way, ‘‘health and social problems are
indeed more common in countries with bigger income inequalities.’’40 People in
Japan, Sweden, and Norway live longer, are less obese, and have fewer teenage
births than people in the United States, the United Kingdom, and Australia,
because their societies are more equal.41
We must also attend to the striking social and political inequalities between
nations to understand the injustice of global health disparities. Gaps in health
measures such as mortality, quality of life, and disease incidence endure across
nations despite increasing levels of overall wealth.42 Yet most medical research is
devoted to treating people in the wealthiest countries, with only a tiny fraction
concerned with illnesses suffered by people in the developing world. Indeed,
medical researchers from the United States and Europe have collected biological
materials and tested new drugs in these politically disadvantaged regions
without distributing the benefits of their research equally.43 Seeing global health
inequities as the result of poverty or unhealthy predispositions of populations in
developing countries will hinder efforts to address the power imbalances that
maintain unethical gaps in health.
Conclusion
There is a long history of using a biological definition of race to make social
inequities seem natural—the result of inherent difference instead of societal
injustice. As Evelynn Hammonds has noted, ‘‘the appeal of a story that links race
to medical and scientific progress is in the way in which it naturalizes the social
order in a racially stratified society such as ours.’’44
While the racial gap in life expectancy widens,45 owing largely to the govern-
ment’s failure to address structural inequities, the poor health of African
Americans opens new markets for pharmaceutical companies. The claim that
race-based drugs will shrink the gap based on genetic difference is a powerful
way to deflect concerns about their unjust social impact and the social inequality
that actually drives poor minority health. At the same time, a color-blind
perspective rationalizes the persistent gaps between white and minority health,
wealth, and status as products of unbiased market operations, not continuing
social injustice.46 Racial minorities have fallen behind whites on every measure,
the theory goes, as a result of their own failings, which make them unable to
compete with whites in purportedly fair social, political, and economic arenas.
Color-blind ideology posits that because racism no longer impedes minority
progress, there is no need for social policies to account for race. Both of these
approaches—race-neutral economics and race-specific genetics—are at play in
explanations for health disparities. It is critical to contest these arguments in
order to tackle the roots of health disparities in social inequality based on race
and to see the need for social change.
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